Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Cwm LLC

Cwm LLC trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 3.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 64,217 shares of the life sciences company’s stock after selling 2,158 shares during the period. Cwm LLC’s holdings in Illumina were worth $8,942,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after acquiring an additional 2,336,935 shares during the last quarter. Polen Capital Management LLC lifted its stake in shares of Illumina by 0.6% in the third quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after buying an additional 29,153 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in Illumina by 5.5% during the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock worth $550,212,000 after acquiring an additional 208,267 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Illumina by 6.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares in the last quarter. Finally, Barclays PLC raised its holdings in Illumina by 120.0% in the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after acquiring an additional 964,709 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN opened at $120.25 on Tuesday. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $229.58. The firm’s 50-day moving average is $132.98 and its two-hundred day moving average is $127.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. Illumina’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.14 earnings per share. As a group, sell-side analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research note on Thursday, January 4th. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Finally, Barclays increased their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $167.70.

Insiders Place Their Bets

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.17% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.